Breast Cancer and Immuno Oncology

View overview page

NeoTRIP: EFS in neoadjuvant atezolizumab with taxane/carboplatin ± anthracycline in high-risk TNBC

Kevin Kalinsky • 22 Oct 2023

Novel treatment options for HER2-low breast cancer

Eva Ciruelos • 23 Oct 2023

Updates in metastatic triple-negative breast cancer at ESMO 2023

Eva Ciruelos • 23 Oct 2023

Real-word efficacy of sacituzumab govitecan in metastatic triple-negative breast cancer

Kevin Kalinsky • 22 Oct 2023

Utilizing neoadjuvant immunotherapies in patients with ER+, HER2- primary breast cancer

Sherene Loi • 20 Oct 2023

CheckMate 7FL: nivo vs PBO in high-risk ER+ HER2- BC with neoadjuvant chemo and adjuvant therapy

Sherene Loi • 20 Oct 2023

ESMO 2023: Key messages for breast cancer treatment

Kevin Kalinsky • 21 Oct 2023

Challenges in identifying predictive markers to ICIs in triple-negative breast cancer

Kevin Kalinsky • 22 Oct 2023

KEYNOTE-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer

Peter Schmid • 22 Oct 2023

BEGONIA: datopotamab deruxtecan and durvalumab in metastatic triple-negative breast cancer

Peter Schmid • 22 Oct 2023

Real-word efficacy of sacituzumab govitecan in metastatic triple-negative breast cancer

Kevin Kalinsky • 21 Oct 2023

The role of targeted therapies in HER2+ and HR+ breast cancer

Yutaka Yamamoto • 4 Jun 2023

NeoALTTO: HER2/CEP17 ratio as a predictive biomarker in HER2+ breast cancer

Michael Gnant • 8 Jun 2023

Improving breast cancer treatment: incorporating immune predictors for better outcomes

Denise M. Wolf • 4 Jun 2023

I-SPY 2: immunotherapy biomarkers in early breast cancer

Denise M. Wolf • 4 Jun 2023

I-SPY 2: advancing outcomes high-risk breast cancer through adapting therapies

Denise M. Wolf • 4 Jun 2023

1
2
3
4
5
…
20
Next